Articles 6 www.thelancet.com/diabetes-endocrinology   Published online April 4, 2014   http://dx.doi.org/10.1016/S2213-8587(14)70029-4one or more measures of patient-reported outcomes  (appendix). Several weight-related quality-of-life domains (eg, physical function, self-esteem, and sexual life) improved more in the exenatide group than in the glargine group (appendix). Discontinuation of study drug because of an adverse  event was more frequent in the exenatide group than in the glargine group (table 3). Only nausea and injection-site reactions led to discontinuation in more than one patient (table 3). The proportion of recipients who reported one or more treatment-related adverse events or serious adverse events was similar in both groups (table 3). Gastrointestinal adverse events characteristic of GLP-1